(NASDAQ: ENTA) Enanta Pharmaceuticals's forecast annual revenue growth rate of 0.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.02%.
Enanta Pharmaceuticals's revenue in 2026 is $66,980,000.On average, 9 Wall Street analysts forecast ENTA's revenue for 2026 to be $2,042,816,721, with the lowest ENTA revenue forecast at $1,722,269,047, and the highest ENTA revenue forecast at $2,267,455,463. On average, 8 Wall Street analysts forecast ENTA's revenue for 2027 to be $1,944,063,893, with the lowest ENTA revenue forecast at $1,512,662,325, and the highest ENTA revenue forecast at $2,312,783,678.
In 2028, ENTA is forecast to generate $2,039,624,593 in revenue, with the lowest revenue forecast at $1,421,947,856 and the highest revenue forecast at $2,416,295,678.